BACKGROUND Posterior cranial fossa is located between the Foramen Magnum and Tentorium Cerebelli. It contains cerebellum, pons and medulla oblongata. Tumours of posterior cranial fossa can affect any of the above structures and can lead to pressure symptoms, neurological deficits or sometimes even death. This study has been conducted at our tertiary care centre. Aims and Objectives-To know the usefulness of intraoperative squash cytology and its diagnostic accuracy in differentiating posterior fossa lesions in correlation with clinical, radiological and histopathological diagnosis. Newer diagnostic modalities like MRI help in detecting these tumours early. Squash cytology and histopathological study diagnose these lesions accurately, which may benefit the patient for further treatment. MATERIALS AND METHODS This is a retrospective descriptive study. A total of 28 cases of posterior cranial fossa lesions were analysed with squash cytology and histopathology correlation. RESULTS Among the 28 cases analysed, 27 cases (96.4%) showed squash cytology with histopathologic correlation. A case of ependymoma was misdiagnosed as embryonal tumour/ medulloblastoma on squash cytology. Male preponderance was noted. The commonest age group was first decade in this study. Cerebellopontine angle was the most common site of the tumours in our study. CONCLUSION Analysing the posterior fossa tumours by squash cytology along with radioimaging in tumour localising and patient's demographics helped in correct histopathological diagnosis for further management and follow-up.

Introduction: Alpha-Methyl Acyl-Co-enzyme Racemase (AMACR, EC 5.1.99.4, also known as P504S) is a mitochondrial and peroxisomal enzyme involved in branched fatty acids oxidation. High dietary intake of branched fatty acids may result in overproduction of AMACR, which is associated with the development of many cancers including prostate, kidney, breast, ovary, liver and gastrointestinal cancers. Several reports have also shown an association between consumption of fat and increased risk of gastric cancer, especially intestinal type gastric carcinomas. Aim: To determine and compare the expression of AMACR in clinical types and various histological grades of gastric carcinomas. Materials and Methods: This was a cross-sectional study conducted from November 2016 to May 2018 at Osmania Medical College/General Hospital, Hyderabad, Telangana, India. The tissue cores of the included biopsied samples of 50 gastric carcinomas, with regions of interest were removed to prepare a tissue microarray and Immunohistochemical (IHC) staining for AMACR was performed. The stained slides were graded based on the intensity of staining and results were evaluated using Chi-square test. Results: Of the 50 gastric carcinomas (32 males and 18 females; age range: 22-80 years) cases studied, 26 were intestinal type and 24 were diffuse type. According to cancer grade, 17 were well differentiated, nine were moderately differentiated and 24 were poorly differentiated. Abnormal AMACR staining was seen in 73.07% (19) cases of well and moderately differentiated adenocarcinoma and 33.33% (8) cases of poorly differentiated adenocarcinoma. The AMACR staining was found to be statistically significantly associated with the differentiation grading of the tumour (p-value 0.016). Abnormal staining for AMACR was seen more in well differentiated compared to moderately and poorly differentiated carcinomas. IHC expression of AMACR showed a statistically significant correlation with Lauren’s type of gastric cancer (p-value 0.005). Conclusion: The AMACR is a racemase present in the cytoplasm; cytoplasmic staining is observed in gastric carcinoma and also with histological grade. Abnormal staining for AMACR was seen more in well differentiated compared to moderately and poorly differentiated carcinomas. The expression of AMACR was significantly higher in intestinal type gastric carcinoma. Hence, the role of AMACR as a target for treating gastric cancer seems to be promising. Further studies are required to establish the role of AMACR as a diagnostic, therapeutic and prognostic tool in gastric malignancies.

Introduction The most common cancer in women is, by far, breast cancer. The incidence and mortality of breast cancer must be reduced by a multidisciplinary strategy that includes education campaigns, preventive measures, screening programmes for early diagnosis, and the availability of treatment facilities. The use of immunohistochemical (IHC) stains with relative specificity for myoepithelial markers has become a mainstay of standard diagnostic breast pathology because the presence and distribution of myoepithelial cells might differ greatly amongst the distinct breast proliferation. Although it has also been reported that DOG1 is expressed in other mesenchymal tumours, DOG1 has been demonstrated to be sensitive and specific for the detection of gastrointestinal stromal tumors (GISTs). Both myoepithelial cells (MECs) and luminal epithelial cells have occasionally displayed DOG1 immunoreactivity in the breast. Materials and methods This prospective cross-sectional study was done in the Department of Pathology at Osmania General Hospital, Hyderabad on 60 cases from June 2017 to June 2019. Female patients with different breast lesions including benign proliferating lesions, ductal carcinoma in-situ (DCIS), and invasive carcinoma breast cases were included in the study. Inflammatory lesions, mesenchymal, and metastatic tumors were excluded. IHC expression of DOG1 as a myoepithelial marker to discriminate invasive from non-invasive breast lesions was evaluated and correlated with clinicopathological features. Results The mean age of the study population was 33.67 ± 8.48 in the benign group and 54.43 ± 12.84 in the malignant group. Fifty percent (15) of the patients with benign lesions belonged to the age group 20-30 years, whereas 26.7% (8) of the patients with malignant lesions belonged to the age group 61-70 years. DOG-1 expression was strongly positive in fibroadenoma, ductal hyperplasia, fibrocystic disease, whereas strongly negative in malignant disease of the breast ( p < 0.0001). P63 expression was strongly positive in benign breast diseases and strongly negative in malignant diseases ( p < 0.0001). Conclusion DOG1 seems to be similar to p63 as a myoepithelial cell marker both in normal breast tissue and in benign lesions. DOG1 is strongly positive in benign breast diseases and strongly negative in malignant breast diseases. Hence, it can be considered as a useful myoepithelial marker in differentiating invasive breast carcinoma and non-invasive breast lesions.